https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-clinical-pipeline-ascend-trial BiopharmaWatch en 2026-10-15T20:15:00.000Z Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001 https://www.biopharmawatch.com/news/MMED/minimed-board-of-directors-independent-company BiopharmaWatch en 2026-10-15T20:10:00.000Z MiniMed Announces Board of Directors for its Next Chapter as an Independent Company https://www.biopharmawatch.com/news/LFST/lifestance-q3-2026-earnings-call BiopharmaWatch en 2026-10-15T20:10:00.000Z LifeStance to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/WRBY/warby-parker-q3-2026-results-announcement BiopharmaWatch en 2026-10-15T20:05:00.000Z Warby Parker to Announce Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/FLGT/fulgent-announces-q3-2026-financial-results BiopharmaWatch en 2026-10-15T20:05:00.000Z Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/EXEL/exelixis-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-15T20:05:00.000Z Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 https://www.biopharmawatch.com/news/GILD/gilead-sciences-q3-2026-financial-results BiopharmaWatch en 2026-10-15T20:05:00.000Z Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-craig-hallum-conference-2026 BiopharmaWatch en 2026-10-15T20:05:00.000Z Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference https://www.biopharmawatch.com/news/MGNX/macrogenics-first-patient-dosed-mgc030-phase-1-study BiopharmaWatch en 2026-10-15T20:05:00.000Z MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-inducement-awards-nasdaq-listing-rule-5635-20261015 BiopharmaWatch en 2026-10-15T20:05:00.000Z Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MOBI/mobia-medical-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-15T20:05:00.000Z Mobia Medical to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/SOLV/solventum-third-quarter-earnings-november-2026 BiopharmaWatch en 2026-10-15T20:05:00.000Z Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026 https://www.biopharmawatch.com/news/SI/shoulder-innovations-q3-2026-financial-results BiopharmaWatch en 2026-10-15T20:05:00.000Z Shoulder Innovations to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-investor-events-2026 BiopharmaWatch en 2026-10-15T20:05:00.000Z LB Pharmaceuticals to Participate in Upcoming Investor Events https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q3-2026-financial-results-release BiopharmaWatch en 2026-10-15T20:05:00.000Z Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-chardan-healthcare-conference-2026 BiopharmaWatch en 2026-10-15T20:05:00.000Z Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-10-15T20:01:00.000Z Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/GH/twinstrand-biosciences-patent-upheld-guardant-health BiopharmaWatch en 2026-10-15T20:01:00.000Z TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent https://www.biopharmawatch.com/news/CDNA/caredx-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-15T20:01:00.000Z CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026 https://www.biopharmawatch.com/news/SNDX/syndax-revuforj-time-best-inventions-2026 BiopharmaWatch en 2026-10-15T20:01:00.000Z Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List https://www.biopharmawatch.com/news/MDXH/mdxhealth-q3-2026-revenue-guidance-suspension BiopharmaWatch en 2026-10-15T20:00:00.000Z MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance https://www.biopharmawatch.com/news/IRD/opus-genetics-opgx-best1-opgx-lca5-retina-rio-2026 BiopharmaWatch en 2026-10-15T20:00:00.000Z Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026 https://www.biopharmawatch.com/news/MDLN/medline-new-distribution-center-van-buren-township BiopharmaWatch en 2026-10-15T18:17:00.000Z Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich. https://www.biopharmawatch.com/news/INGN/inogen-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-15T17:00:00.000Z Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/NTRA/natera-signatera-mrd-test-time-best-inventions-2026 BiopharmaWatch en 2026-10-15T16:46:00.000Z Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026 https://www.biopharmawatch.com/news/CDRE/alimentiv-ibus-partnership-expansion-ius-star-training BiopharmaWatch en 2026-10-15T16:15:00.000Z Alimentiv et l'International Bowel Ultrasound Group étendent leur partenariat pour inclure la formation en échographie dans le cadre des essais cliniques. https://www.biopharmawatch.com/news/MDT/medtronic-separation-minimed-group BiopharmaWatch en 2026-10-15T14:00:00.000Z Medtronic Completes Separation of MiniMed Group, Inc. https://www.biopharmawatch.com/news/LLY/lilly-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-15T14:00:00.000Z Lilly confirms date and conference call for third-quarter 2026 financial results announcement https://www.biopharmawatch.com/news/MMED/minimed-completes-separation-from-medtronic BiopharmaWatch en 2026-10-15T14:00:00.000Z MiniMed Completes Separation from Medtronic https://www.biopharmawatch.com/news/RVMD/rasonque-positive-chmp-opinion-pancreatic-cancer BiopharmaWatch en 2026-10-15T13:45:00.000Z Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-ceo-adc-payload-strategy BiopharmaWatch en 2026-10-15T13:20:00.000Z Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner https://www.biopharmawatch.com/news/NRXS/neuraxis-medical-policy-coverage-expansion BiopharmaWatch en 2026-10-15T13:18:00.000Z NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives https://www.biopharmawatch.com/news/CODX/co-diagnostics-pcr-platform-plague-detection BiopharmaWatch en 2026-10-15T13:15:00.000Z Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection https://www.biopharmawatch.com/news/EDSA/edesa-biotech-fda-ind-clearance-phase-2-vitiligo-study BiopharmaWatch en 2026-10-15T13:15:00.000Z Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study https://www.biopharmawatch.com/news/LEXX/lexaria-animal-study-glp-1-a26-1-results BiopharmaWatch en 2026-10-15T13:13:06.000Z Lexaria Announces Results from Animal Study GLP-1-A26-1 https://www.biopharmawatch.com/news/CVS/cvs-health-midlife-collective-collaboration BiopharmaWatch en 2026-10-15T13:00:00.000Z CVS Health collaborates with The Midlife Collective to redefine a woman's midlife health journey https://www.biopharmawatch.com/news/NTHI/uae-banking-heavyweight-joins-neonc-brain-cancer-drug-development BiopharmaWatch en 2026-10-15T12:57:00.000Z UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-first-patient-dosed-car-t-study BiopharmaWatch en 2026-10-15T12:46:00.000Z Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma https://www.biopharmawatch.com/news/RXRX/recursion-sanofi-first-in-class-immunology-candidate BiopharmaWatch en 2026-10-15T12:45:00.000Z Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration https://www.biopharmawatch.com/news/ONMD/onemednet-expands-hospital-network-12-hospitals BiopharmaWatch en 2026-10-15T12:45:00.000Z OneMedNet Adds Leading Hospital System Provider Network, Expanding By Up to 12 Hospitals https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-acquires-minority-stake-sod-sciences BiopharmaWatch en 2026-10-15T12:45:00.000Z Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-q3-2026-financial-results-call BiopharmaWatch en 2026-10-15T12:32:00.000Z Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/BEAT/heartbeam-joins-exit-cvd-consortium-ecg-monitoring BiopharmaWatch en 2026-10-15T12:31:00.000Z HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients https://www.biopharmawatch.com/news/RXRX/recursion-pricing-200-million-offering-class-a-stock BiopharmaWatch en 2026-10-15T12:30:00.000Z Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-eanm-2026-atnm-400-study BiopharmaWatch en 2026-10-15T12:30:00.000Z Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer https://www.biopharmawatch.com/news/CAI/caris-life-sciences-third-quarter-2026-results BiopharmaWatch en 2026-10-15T12:30:00.000Z Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/PYPD/polypid-virtual-investor-day-october-2026 BiopharmaWatch en 2026-10-15T12:30:00.000Z PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026 https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-labeling-review-ketamine BiopharmaWatch en 2026-10-15T12:27:00.000Z NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine https://www.biopharmawatch.com/news/RXRX/recursion-200-million-offering-clinical-updates-partnership BiopharmaWatch en 2026-10-15T12:22:00.000Z Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone https://www.biopharmawatch.com/news/DRMA/dermata-positive-results-tome-treatment BiopharmaWatch en 2026-10-15T12:05:00.000Z Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment https://www.biopharmawatch.com/news/GH/guardant-health-blood-test-colorectal-cancer-screening BiopharmaWatch en 2026-10-15T12:05:00.000Z Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests https://www.biopharmawatch.com/news/NTHI/neonc-ceo-address-global-health-summit-2026 BiopharmaWatch en 2026-10-15T12:00:48.000Z NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026 https://www.biopharmawatch.com/news/LLY/omvoh-achieves-corticosteroid-free-remission BiopharmaWatch en 2026-10-15T12:00:00.000Z New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year https://www.biopharmawatch.com/news/XERS/xeris-biopharma-leadership-endocrinology-data-disclosures BiopharmaWatch en 2026-10-15T12:00:00.000Z Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-q3-2026-financial-results BiopharmaWatch en 2026-10-15T12:00:00.000Z Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/GEHC/ge-healthcare-mini-trace-magni-ce-mark-copper-64 BiopharmaWatch en 2026-10-15T12:00:00.000Z GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68 https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-chest-2026 BiopharmaWatch en 2026-10-15T12:00:00.000Z bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026 https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-conference-call-q3-2026-results BiopharmaWatch en 2026-10-15T12:00:00.000Z Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-third-quarter-2026-results BiopharmaWatch en 2026-10-15T12:00:00.000Z PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026 https://www.biopharmawatch.com/news/HUMA/humacyte-commercial-update-symvess-adoption BiopharmaWatch en 2026-10-15T12:00:00.000Z Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals https://www.biopharmawatch.com/news/TARA/protara-therapeutics-thrive-3-trial-enrollment-completed BiopharmaWatch en 2026-10-15T12:00:00.000Z Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-private-placement-200-million BiopharmaWatch en 2026-10-15T12:00:00.000Z First Tracks Biotherapeutics Announces $200 Million Private Placement https://www.biopharmawatch.com/news/IRLA/irulya-therapeutics-craig-hallum-conference-2026 BiopharmaWatch en 2026-10-15T12:00:00.000Z IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference https://www.biopharmawatch.com/news/DXR/daxor-commercial-expansion-blood-volume-diagnostic-platform BiopharmaWatch en 2026-10-15T12:00:00.000Z Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26 https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-phase-2-study-ven-sobafusp-alfa-igan BiopharmaWatch en 2026-10-15T12:00:00.000Z Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-ind-eik1006-prostate-cancer BiopharmaWatch en 2026-10-15T12:00:00.000Z Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer https://www.biopharmawatch.com/news/LEGN/legend-biotech-fda-clearance-lb2501-car-t-therapy BiopharmaWatch en 2026-10-15T12:00:00.000Z Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy https://www.biopharmawatch.com/news/EPRX/eupraxia-reaches-enrollment-target-resolve-trial-eprx BiopharmaWatch en 2026-10-15T12:00:00.000Z Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis https://www.biopharmawatch.com/news/MENS/jyong-biotech-texas-facility-commercialization BiopharmaWatch en 2026-10-15T12:00:00.000Z Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-q3-2026-results-announcement BiopharmaWatch en 2026-10-15T12:00:00.000Z Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026 https://www.biopharmawatch.com/news/HELP/helus-pharma-appoints-dr-suresh-durgam-board BiopharmaWatch en 2026-10-15T11:30:09.000Z Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors https://www.biopharmawatch.com/news/LH/labcorp-acquires-bioreference-health-assets BiopharmaWatch en 2026-10-15T11:30:00.000Z Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-appoints-matt-david-cfo BiopharmaWatch en 2026-10-15T11:30:00.000Z Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-phase-3-selva-results-pedra-2026 BiopharmaWatch en 2026-10-15T11:30:00.000Z Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference https://www.biopharmawatch.com/news/SPRC/scisparc-transformation-agentic-ai-technologies BiopharmaWatch en 2026-10-15T11:06:00.000Z SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies https://www.biopharmawatch.com/news/NEO/neogenomics-expands-indica-labs-partnership-ai-pathology BiopharmaWatch en 2026-10-15T11:05:00.000Z NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology https://www.biopharmawatch.com/news/LGND/ligand-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-15T11:00:00.000Z Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026 https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-chardan-healthcare-conference BiopharmaWatch en 2026-10-15T11:00:00.000Z Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q3-2026-financial-results-webcast BiopharmaWatch en 2026-10-15T11:00:00.000Z Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026 https://www.biopharmawatch.com/news/INSM/insmed-palm-clinical-development-program-chest-2026 BiopharmaWatch en 2026-10-15T11:00:00.000Z Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026 https://www.biopharmawatch.com/news/KRYS/krystal-biotech-kb113-gorlin-syndrome-results BiopharmaWatch en 2026-10-15T11:00:00.000Z Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome https://www.biopharmawatch.com/news/IMCR/immunocore-phase-1-trial-imc-s118ai-type-1-diabetes BiopharmaWatch en 2026-10-15T11:00:00.000Z Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-phase-2b-clover-wam-results BiopharmaWatch en 2026-10-15T11:00:00.000Z Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentations-world-vaccine-congress-europe-2026 BiopharmaWatch en 2026-10-15T11:00:00.000Z Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026 https://www.biopharmawatch.com/news/ADMA/adma-biologics-ivig-manufacturing-process-publication BiopharmaWatch en 2026-10-15T11:00:00.000Z ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process https://www.biopharmawatch.com/news/CRON/cronos-acquires-canadelaar-europe-cannabis-leader BiopharmaWatch en 2026-10-15T11:00:00.000Z Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis Company https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-fda-anaphylm-nda-resubmission BiopharmaWatch en 2026-10-15T11:00:00.000Z Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-ser-428-idweek-2026 BiopharmaWatch en 2026-10-15T11:00:00.000Z Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 https://www.biopharmawatch.com/news/ANL/adlai-nortye-clinical-collaboration-lilly-merck BiopharmaWatch en 2026-10-15T11:00:00.000Z Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab https://www.biopharmawatch.com/news/PFSA/profusa-receives-iso-13485-certification-gmed BiopharmaWatch en 2026-10-15T10:30:00.000Z Profusa Receives ISO 13485:2016 Certificate from GMED https://www.biopharmawatch.com/news/RMTI/rockwell-medical-q3-2026-results-release BiopharmaWatch en 2026-10-15T10:00:00.000Z Rockwell Medical to Release Third Quarter 2026 Results on Thursday, November 12, 2026 https://www.biopharmawatch.com/news/AZN/insitro-astrazeneca-ai-therapeutics-collaboration BiopharmaWatch en 2026-10-15T10:00:00.000Z insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies https://www.biopharmawatch.com/news/ZYME/zymeworks-participation-investor-conferences-q3-2026-results BiopharmaWatch en 2026-10-15T10:00:00.000Z Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EVO/evotec-appoints-dr-joanna-holbrook-cso BiopharmaWatch en 2026-10-15T06:04:00.000Z Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board https://www.biopharmawatch.com/news/ARGX/argenx-third-quarter-2026-financial-results-update BiopharmaWatch en 2026-10-15T05:00:00.000Z argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026 https://www.biopharmawatch.com/news/TAK/takeda-orzeyful-launch-japan-china BiopharmaWatch en 2026-10-15T00:30:00.000Z Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 https://www.biopharmawatch.com/news/DXCM/dexcom-connect-study-type-2-diabetes BiopharmaWatch en 2026-10-14T21:10:00.000Z Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-update-vqw-765-clinical-development BiopharmaWatch en 2026-10-14T21:00:00.000Z Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program https://www.biopharmawatch.com/news/CERS/cerus-corporation-workshop-aabb-annual-meeting-2026 BiopharmaWatch en 2026-10-14T20:30:00.000Z Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-kristine-ball-appointment-phase-3-trial BiopharmaWatch en 2026-10-14T20:30:00.000Z Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year https://www.biopharmawatch.com/news/CMPX/compass-announces-inducement-grants-nasdaq-listing-rule-5635-c-4 BiopharmaWatch en 2026-10-14T20:30:00.000Z Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CHRS/coherus-oncology-webcast-interim-tagmokitug-data BiopharmaWatch en 2026-10-14T20:30:00.000Z Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026 https://www.biopharmawatch.com/news/IBRX/fda-expands-anktiva-approval-non-muscle-invasive-bladder-cancer BiopharmaWatch en 2026-10-14T20:18:00.000Z FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-activates-intermountain-health-lds-hospital BiopharmaWatch en 2026-10-14T20:15:00.000Z Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma https://www.biopharmawatch.com/news/OABI/omniab-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-14T20:05:00.000Z OmniAb to Report Third Quarter 2026 Financial Results on October 30 https://www.biopharmawatch.com/news/TDOC/teladoc-health-third-quarter-2026-results BiopharmaWatch en 2026-10-14T20:05:00.000Z Teladoc Health to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-q3-2026-financial-results BiopharmaWatch en 2026-10-14T20:05:00.000Z Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/RZLT/rezolute-completes-enrollment-phase-3-upLIFT-study-ersodetug BiopharmaWatch en 2026-10-14T20:05:00.000Z Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-appoints-jeff-farrow-board BiopharmaWatch en 2026-10-14T20:05:00.000Z Lisata Therapeutics Appoints Jeff Farrow to Board of Directors https://www.biopharmawatch.com/news/PACB/pacbio-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-14T20:05:00.000Z PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-earnings-conference-call-november-2026 BiopharmaWatch en 2026-10-14T20:01:00.000Z Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/MNKD/mannkind-participate-chardan-healthcare-conference BiopharmaWatch en 2026-10-14T20:01:00.000Z MannKind to Participate in the Chardan Healthcare Conference https://www.biopharmawatch.com/news/MDXG/mimedx-third-quarter-2026-results-conference-call BiopharmaWatch en 2026-10-14T20:01:00.000Z MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026 https://www.biopharmawatch.com/news/BLTE/belite-bio-tinlarebant-stargardt-disease-submission BiopharmaWatch en 2026-10-14T20:00:00.000Z Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1 https://www.biopharmawatch.com/news/ACB/aurora-cannabis-reject-curaleaf-bid BiopharmaWatch en 2026-10-14T19:48:00.000Z Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside https://www.biopharmawatch.com/news/JAGX/jaguar-health-special-stock-dividend-update BiopharmaWatch en 2026-10-14T16:15:00.000Z Jaguar Health Provides Update Regarding Special Stock Dividend https://www.biopharmawatch.com/news/MRK/merck-advance-bioanalytical-facility-west-point BiopharmaWatch en 2026-10-14T16:03:38.000Z Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus https://www.biopharmawatch.com/news/VALN/valneva-present-hold-investor-meetings-upcoming-u-s-european-healthcare BiopharmaWatch en 2026-10-14T15:45:00.000Z Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences https://www.biopharmawatch.com/news/SDGR/schrodinger-research-lithium-ion-battery-insights BiopharmaWatch en 2026-10-14T15:05:00.000Z Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry https://www.biopharmawatch.com/news/CYH/community-health-systems-webcast-q3-2026-call BiopharmaWatch en 2026-10-14T15:00:00.000Z Community Health Systems to Webcast Third Quarter 2026 Conference Call https://www.biopharmawatch.com/news/NTHI/neonc-strengthens-boardroom-brain-cancer-drug-development BiopharmaWatch en 2026-10-14T14:18:00.000Z NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development https://www.biopharmawatch.com/news/ONCY/oncolytics-goblet-study-update-clinical-data BiopharmaWatch en 2026-10-14T13:30:00.000Z Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment https://www.biopharmawatch.com/news/ILMN/illumina-bioinsight-platform-launch BiopharmaWatch en 2026-10-14T13:15:00.000Z Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs https://www.biopharmawatch.com/news/SYK/stryker-sonopet-3-launch-fda-clearance BiopharmaWatch en 2026-10-14T13:03:00.000Z Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal https://www.biopharmawatch.com/news/JAGX/positive-results-crofelemer-sbs-if-jagx BiopharmaWatch en 2026-10-14T13:00:00.000Z Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer https://www.biopharmawatch.com/news/BIO/bio-rad-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-14T13:00:00.000Z Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/ELV/elevance-health-foundation-patient-safety-prize-winners BiopharmaWatch en 2026-10-14T13:00:00.000Z Elevance Health Foundation Announces Winners of Inaugural Patient Safety Prize Through Innovative Community Action Leadership Program https://www.biopharmawatch.com/news/CVS/minuteclinic-joint-commission-accreditation-cvs BiopharmaWatch en 2026-10-14T13:00:00.000Z MinuteClinic earns seventh consecutive Joint Commission accreditation, including first evaluation under Medical Center standards https://www.biopharmawatch.com/news/EDIT/editas-medicine-esgct-congress-presentations BiopharmaWatch en 2026-10-14T13:00:00.000Z Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference https://www.biopharmawatch.com/news/CARL/carlsmed-launches-aprevo-lumbar-system BiopharmaWatch en 2026-10-14T13:00:00.000Z Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System https://www.biopharmawatch.com/news/FEMY/femasys-doubles-enrolling-sites-fembloc-finale-trial BiopharmaWatch en 2026-10-14T13:00:00.000Z Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control https://www.biopharmawatch.com/news/ICU/seastar-medical-kevin-chung-combat-nephrology-award-2026 BiopharmaWatch en 2026-10-14T12:37:00.000Z SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award https://www.biopharmawatch.com/news/SABS/sab-bio-participate-chardan-healthcare-conference BiopharmaWatch en 2026-10-14T12:30:29.000Z SAB BIO to Participate in Chardan 10th Annual Healthcare Conference https://www.biopharmawatch.com/news/RARE/ultragenyx-sells-priority-review-voucher-203-million BiopharmaWatch en 2026-10-14T12:30:13.000Z Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million https://www.biopharmawatch.com/news/EOLS/evolus-expands-hair-restoration-pipeline BiopharmaWatch en 2026-10-14T12:30:00.000Z Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program https://www.biopharmawatch.com/news/VIR/vir-gilead-collaboration-pro-xten-tce-development BiopharmaWatch en 2026-10-14T12:30:00.000Z Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srp-1003-preclinical-data-dmpk-rna BiopharmaWatch en 2026-10-14T12:30:00.000Z Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting https://www.biopharmawatch.com/news/CAI/caris-life-sciences-esmo-2026-ai-precision-medicine BiopharmaWatch en 2026-10-14T12:30:00.000Z Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026 https://www.biopharmawatch.com/news/INMB/inmune-bio-quantum-computing-partnership-alzheimers-research BiopharmaWatch en 2026-10-14T12:30:00.000Z INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™ https://www.biopharmawatch.com/news/FBLG/fibrobiologics-australian-patent-cellular-blend BiopharmaWatch en 2026-10-14T12:30:00.000Z FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-efficacy-study BiopharmaWatch en 2026-10-14T12:30:00.000Z Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-fda-acceptance-tabelecleucel BiopharmaWatch en 2026-10-14T12:05:00.000Z Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration https://www.biopharmawatch.com/news/IPSC/century-therapeutics-2026-jefferies-conference BiopharmaWatch en 2026-10-14T12:05:00.000Z Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/BLLN/billiontoone-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-14T12:05:00.000Z BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-q3-2026-revenue-guidance BiopharmaWatch en 2026-10-14T12:05:00.000Z MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-boston-development-leadership BiopharmaWatch en 2026-10-14T12:01:00.000Z MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies https://www.biopharmawatch.com/news/NTHI/neonc-technologies-appoints-ali-alabedin-board BiopharmaWatch en 2026-10-14T12:00:27.000Z NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors https://www.biopharmawatch.com/news/COYA/coya-open-label-extension-phase-2-3-alstars-trial BiopharmaWatch en 2026-10-14T12:00:00.000Z Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS https://www.biopharmawatch.com/news/MDT/medtronic-final-results-minimed-exchange-offer BiopharmaWatch en 2026-10-14T12:00:00.000Z Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer https://www.biopharmawatch.com/news/BMRN/biomarin-acquisition-alesta-therapeutics BiopharmaWatch en 2026-10-14T12:00:00.000Z 1cBio Received Shareholder Proceeds Upon Closing of BioMarin Pharmaceutical Inc.'s Acquisition of Alesta Therapeutics https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-financing-private-placement BiopharmaWatch en 2026-10-14T12:00:00.000Z Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement https://www.biopharmawatch.com/news/DXR/daxor-hfsa-2026-clinical-data BiopharmaWatch en 2026-10-14T12:00:00.000Z Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026 https://www.biopharmawatch.com/news/ADAG/adagene-hc-wainwright-immune-cell-engager-conference BiopharmaWatch en 2026-10-14T12:00:00.000Z Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference https://www.biopharmawatch.com/news/BIVI/biovie-bezisterim-parkinsons-long-covid-ana2026 BiopharmaWatch en 2026-10-14T12:00:00.000Z BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting https://www.biopharmawatch.com/news/LFWD/lifeward-rewalk-exoskeleton-long-term-use-study BiopharmaWatch en 2026-10-14T12:00:00.000Z Lifeward’s ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study https://www.biopharmawatch.com/news/IMDX/imdex-new-sales-leader-graftassuredx-launch BiopharmaWatch en 2026-10-14T12:00:00.000Z iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch https://www.biopharmawatch.com/news/IMMP/immutep-monash-university-lag-3-research-funding BiopharmaWatch en 2026-10-14T12:00:00.000Z Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research https://www.biopharmawatch.com/news/TPST/tempest-appoints-john-frederick-board-directors BiopharmaWatch en 2026-10-14T12:00:00.000Z Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise https://www.biopharmawatch.com/news/GMED/globus-medical-showcase-nass-2026 BiopharmaWatch en 2026-10-14T12:00:00.000Z Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026 https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-q3-2026-results-conference-call BiopharmaWatch en 2026-10-14T12:00:00.000Z Alignment Healthcare to Announce Third Quarter 2026 Financial Results and Host Conference Call Thursday, Oct. 29, 2026 https://www.biopharmawatch.com/news/CAMP/camp4-participate-chardan-healthcare-conference BiopharmaWatch en 2026-10-14T12:00:00.000Z CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-chardan-healthcare-conference-2026 BiopharmaWatch en 2026-10-14T12:00:00.000Z Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-arow-mapt-phase-1-2a-results BiopharmaWatch en 2026-10-14T11:30:00.000Z Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers https://www.biopharmawatch.com/news/GLAS/glass-house-brands-gacp-certifications BiopharmaWatch en 2026-10-14T11:30:00.000Z Glass House Brands Receives Good Agricultural and Collection Practice (GACP) Certifications https://www.biopharmawatch.com/news/PROF/tulsa-abstracts-interventional-mri-symposium-2026 BiopharmaWatch en 2026-10-14T11:30:00.000Z TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity https://www.biopharmawatch.com/news/NEO/neogenomics-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-14T11:05:00.000Z NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026 https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-vk2735-phase-3-obesity BiopharmaWatch en 2026-10-14T11:05:00.000Z Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity https://www.biopharmawatch.com/news/IVVD/invivyd-flintlock-phase-2-study-vyd2311-long-covid BiopharmaWatch en 2026-10-14T11:01:00.000Z Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome https://www.biopharmawatch.com/news/ANGO/humana-medicare-advantage-coverage-nanoknife-ire BiopharmaWatch en 2026-10-14T11:00:00.000Z AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer https://www.biopharmawatch.com/news/ZLAB/zai-lab-zl-1503-clinical-trial-data-acaa-meeting BiopharmaWatch en 2026-10-14T11:00:00.000Z Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-partnership-clayman-thyroid-center BiopharmaWatch en 2026-10-14T11:00:00.000Z Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center https://www.biopharmawatch.com/news/INSM/insmed-new-data-cheast-idweek-2026 BiopharmaWatch en 2026-10-14T11:00:00.000Z Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026 https://www.biopharmawatch.com/news/AXGN/axogen-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-14T11:00:00.000Z Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026 https://www.biopharmawatch.com/news/PBLS/parabilis-zolucatetide-fap-clinical-study BiopharmaWatch en 2026-10-14T11:00:00.000Z Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-positive-results-elevate-45-201-study BiopharmaWatch en 2026-10-14T11:00:00.000Z Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-elevate-44-201-cohort-3-initiation BiopharmaWatch en 2026-10-14T11:00:00.000Z Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study https://www.biopharmawatch.com/news/ETON/eton-aquestive-licensing-agreement-libervant BiopharmaWatch en 2026-10-14T10:50:00.000Z Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film https://www.biopharmawatch.com/news/PFE/pfizer-clinical-advancements-infectious-diseases-idweek-2026 BiopharmaWatch en 2026-10-14T10:45:00.000Z Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026 https://www.biopharmawatch.com/news/CMPS/compass-pathways-trd-awareness-day BiopharmaWatch en 2026-10-14T10:30:00.000Z Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-ema-orphan-drug-designation-qrx003 BiopharmaWatch en 2026-10-14T10:30:00.000Z Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome https://www.biopharmawatch.com/news/OCGN/ocugen-roots-pharmaceutical-license-agreement-ocu400 BiopharmaWatch en 2026-10-14T10:30:00.000Z Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa https://www.biopharmawatch.com/news/VSTM/verastem-oncology-pricing-offering-common-stock BiopharmaWatch en 2026-10-14T10:04:00.000Z Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/VSTM/verastem-oncology-ceo-transition-plan BiopharmaWatch en 2026-10-14T10:01:00.000Z Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan https://www.biopharmawatch.com/news/VSTM/vs-7375-anti-tumor-activity-kras-g12d-cancers BiopharmaWatch en 2026-10-14T10:00:00.000Z VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) https://www.biopharmawatch.com/news/RMTI/rockwell-medical-asn-kidney-week-2026 BiopharmaWatch en 2026-10-14T10:00:00.000Z Rockwell Medical to Exhibit at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/MEDS/datameds-licenses-reboot-health-ai-glp1-platform BiopharmaWatch en 2026-10-14T09:48:00.000Z DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform https://www.biopharmawatch.com/news/COSM/cosmos-health-active-us-subscriptions-growth BiopharmaWatch en 2026-10-14T09:30:00.000Z Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription https://www.biopharmawatch.com/news/CVS/cvs-pharmacy-first-pharmacy-focused-location-boston BiopharmaWatch en 2026-10-14T09:00:00.000Z CVS Pharmacy(R) Celebrates Opening of First Pharmacy-Focused Location in Boston Area https://www.biopharmawatch.com/news/APVO/aptevo-showcase-multispecific-platform-sitc-2026 BiopharmaWatch en 2026-10-14T08:46:00.000Z Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/ALVO/alvotech-advanz-biosimilar-eylea-regulatory-submission BiopharmaWatch en 2026-10-14T08:30:00.000Z Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg https://www.biopharmawatch.com/news/VBIO/valion-bio-velocity-bioworks-domestic-cdmo-surge BiopharmaWatch en 2026-10-14T08:15:00.000Z With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge https://www.biopharmawatch.com/news/HEPA/hepion-acquisition-gravitas-life-sciences-update BiopharmaWatch en 2026-10-14T08:01:00.000Z Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update https://www.biopharmawatch.com/news/DHR/danaher-nvidia-advance-autonomous-science BiopharmaWatch en 2026-10-14T06:00:00.000Z Danaher Collaborates with NVIDIA to Advance Autonomous Science https://www.biopharmawatch.com/news/PHAR/pharming-phase-ii-leniolisib-data-esid-2026 BiopharmaWatch en 2026-10-14T06:00:00.000Z Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026 https://www.biopharmawatch.com/news/TLX/telix-eanm-trials-theranostics BiopharmaWatch en 2026-10-14T05:00:00.000Z Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM https://www.biopharmawatch.com/news/CNTN/canton-strategic-holdings-q3-ecosystem-update BiopharmaWatch en 2026-10-14T00:00:00.000Z Canton Strategic Holdings, Inc. Delivers Third Quarter Canton Network Ecosystem Update https://www.biopharmawatch.com/news/RYTM/rhythm-launch-imcivree-japan-acquired-hypothalamic-obesity BiopharmaWatch en 2026-10-13T23:30:00.000Z Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity https://www.biopharmawatch.com/news/LQDA/liquidia-settlement-united-therapeutics-yutrepia-pah BiopharmaWatch en 2026-10-13T21:44:00.000Z Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH https://www.biopharmawatch.com/news/GENB/generate-biomedicines-zealand-pharma-collaboration BiopharmaWatch en 2026-10-13T20:30:00.000Z Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases https://www.biopharmawatch.com/news/GENB/zealand-generate-collaboration-ai-metabolic-diseases BiopharmaWatch en 2026-10-13T20:30:00.000Z Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases